Assisted Outpatient Treatment - Surrender or Seizure of Firearms
HB1306 requires the Maryland Department of Health to create three specialized clinics dedicated to the management and treatment of sickle cell disease, located in Montgomery County, Harford County, and one county on the Eastern Shore. The clinics must operate under a hub-and-spoke model and provide routine care, pain management, genetic counseling, mental health services, surveillance, patient education, telehealth access to specialists, behavioral health and social supports, infusion therapy, and coordination with primary care and social service agencies. The bill also directs the clinics to partner with community-based organizations to address barriers such as transportation, housing, and nutrition.
In addition to the clinic network, the bill establishes a scholarship program for medical residents who specialize in benign or classical hematology with a focus on sickle cell care. Recipients would receive financial assistance in exchange for a commitment to practice in Maryland for a minimum period after residency or fellowship. The Department is instructed to use federal funding for the scholarship program to the extent practicable.
The bill would add new sections 18-510 and 18-511 to the Health-General Article, creating a new state mandate for sickle cell-specific clinical infrastructure and workforce development. It would require a $6 million appropriation in fiscal year 2027 to support clinic operations, staffing, training, and social support services, and it would require annual reporting to the General Assembly on clinic operations, patient outcomes, access, telemedicine use, and impact on health disparities. The measure would affect the Maryland Department of Health, community-based organizations, nonprofit partners, medical residents, and people living with sickle cell disease.
The bill appears generally supportive and public-health oriented, with a focus on improving access to specialized care for a population that often faces significant disparities. The structure of the bill suggests broad interest in expanding treatment capacity, strengthening community partnerships, and building a long-term workforce pipeline for sickle cell care. No committee votes or transcript discussion were provided, so there is no recorded opposition or amendment debate in the supplied materials.
The main likely points of contention are the required state appropriation, the feasibility of establishing and staffing three specialized clinics in the specified regions, and the use of federal versus state funding for the scholarship program. Policymakers may also differ on whether a disease-specific clinic model is the best use of resources compared with broader investments in hematology, primary care, or social services. Because no hearing transcript or vote record was provided, no specific member or stakeholder opposition is identifiable from the supplied context.